Detalles de la búsqueda
1.
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.
N Engl J Med
; 387(21): 1957-1968, 2022 11 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36346079
2.
Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Oncology
; 102(3): 239-251, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37729889
3.
RECAM-J 2023-Validation and development of the Japanese version of RECAM for the diagnosis of drug-induced liver injury.
Hepatol Res
; 54(6): 503-512, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38642343
4.
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
J Med Virol
; 95(1): e28210, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36222204
5.
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Invest New Drugs
; 41(2): 340-349, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36995548
6.
Japanese subgroup analysis of GLIMMER: A global Phase IIb study of linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.
Hepatol Res
; 53(7): 629-640, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36852705
7.
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Hepatol Res
; 53(1): 61-71, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36070216
8.
Significant association between HLA-B*35:01 and onset of drug-induced liver injury caused by Kampo medicines in Japanese patients.
Hepatol Res
; 53(5): 440-449, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36583370
9.
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
J Viral Hepat
; 29(7): 551-558, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35548866
10.
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Invest New Drugs
; 40(6): 1290-1297, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36152108
11.
Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
Clin Infect Dis
; 73(9): e3349-e3354, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33544129
12.
Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
J Med Virol
; 93(11): 6247-6256, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34170517
13.
Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Oncology
; 99(8): 507-517, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33946070
14.
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy.
Oncology
; 99(5): 327-335, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33677453
15.
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
Oncology
; 99(8): 491-498, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34000725
16.
Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: a randomized pilot study.
Esophagus
; 18(3): 669-675, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33221955
17.
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Oncology
; 98(11): 787-797, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32882687
18.
Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis.
Hepatol Res
; 50(11): 1234-1243, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32914512
19.
Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen.
Hepatol Res
; 49(10): 1121-1126, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31209976
20.
Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Hepatol Res
; 49(3): 264-270, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30171740